{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Squamous+Cell+Lung+Carcinoma", "query": { "condition": "Stage IV Squamous Cell Lung Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 213, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Squamous+Cell+Lung+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T02:19:33.522Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)", "Nonsmall Cell Lung Cancer, Stage IIIB", "Nonsmall Cell Lung Cancer, Stage IV" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-11-16", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 11, "location_summary": "Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014815" }, { "nct_id": "NCT02154490", "title": "Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "FGFR Inhibitor AZD4547", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rilotumumab", "type": "BIOLOGICAL" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1864, "start_date": "2014-07-08", "completion_date": "2022-04-15", "has_results": true, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 998, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154490" }, { "nct_id": "NCT01107626", "title": "Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed Disodium Heptahydrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1516, "start_date": "2010-10-25", "completion_date": "2021-08-17", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 434, "location_summary": "Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Fairfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Monterey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107626" }, { "nct_id": "NCT01737502", "title": "Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Small Cell Lung Carcinoma", "Squamous Cell Lung Carcinoma", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Auranofin", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-05-14", "completion_date": "2023-04-24", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01737502" }, { "nct_id": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anaplastic Thyroid Cancer", "Insular Thyroid Cancer", "Metastatic Parathyroid Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Parathyroid Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Thyroid Cancer", "Recurrent Verrucous Carcinoma of the Larynx", "Stage III Follicular Thyroid Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Non-small Cell Lung Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVA Basal Cell Carcinoma of the Lip", "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Lymphoepithelioma of the Oropharynx", "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVA Papillary Thyroid Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVB Basal Cell Carcinoma of the Lip", "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Lymphoepithelioma of the Oropharynx", "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVB Papillary Thyroid Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVC Basal Cell Carcinoma of the Lip", "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Lymphoepithelioma of the Oropharynx", "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVC Papillary Thyroid Cancer", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Thryoid Gland Nonmedullary Carcinoma", "Thyroid Gland Medullary Carcinoma", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068497" }, { "nct_id": "NCT02426658", "title": "Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2015-05", "completion_date": "2022-10-07", "has_results": true, "last_update_posted_date": "2023-10-12", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02426658" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT00585377", "title": "Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Bevacizumab and Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2007-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585377" }, { "nct_id": "NCT05837767", "title": "A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Invasive Ductal Breast Carcinoma", "Invasive Ductal Breast Carcinoma Stage IV", "Lobular Breast Carcinoma", "Lobular Breast Carcinoma Stage IV", "Non Small Cell Lung Cancer", "NSCLC", "Gastrointestinal Cancer", "Gastrointestinal Squamous Cell Cancer", "Gastrointestinal Adenocarcinoma", "Pancreatic Cancer", "Bladder Cancer", "Renal Cell Carcinoma", "Melanoma", "Sarcoma", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Palliative radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2023-07-24", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05837767" }, { "nct_id": "NCT02535325", "title": "Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma", "Stage III Lung Adenocarcinoma AJCC v7", "Stage III Lung Large Cell Carcinoma AJCC v7", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Adenocarcinoma AJCC v7", "Stage IIIA Lung Large Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Adenocarcinoma AJCC v7", "Stage IIIB Lung Large Cell Carcinoma AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Adenocarcinoma AJCC v7", "Stage IV Lung Large Cell Carcinoma AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Methoxyamine", "type": "DRUG" }, { "name": "Methoxyamine Hydrochloride", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-09-30", "completion_date": "2022-06-14", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-06-11T02:19:33.522Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02535325" } ] }